Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (201-210 of 260) with videos related to

Pageof 26
Sort By:
The Journal of Rheumatology|July 9, 2008
Clinical and genetic registries in psoriatic diseaseDafna D Gladman, Proton Rahman, Gerald G Krueger, et al.
The Journal of Rheumatology|December 1, 2022
Work-Related Issues and Physical and Psychological Burden in Canadian Patients With Axial Spondyloarthritis: Results From the International Map of Axial SpondyloarthritisRobert D Inman, Marco Garrido-Cumbrera, Jonathan Chan, et al.
Journal of Community Genetics|April 9, 2011
Community genetics. Its definition 2010Leo P Ten Kate, Lihadh Al-Gazali, Sonia Anand, et al.
Human Genetics|February 19, 2026
Horizon: CNV interpretation through rapid automated ACMG-aligned pathogenicity analysisMariam Eldesouky, Suhana Shiyas, Amirul Islam, et al.
Rheumatology and Therapy|August 21, 2020
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 WeeksHelena Marzo-Ortega, Philip J Mease, Proton Rahman, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
The Journal of Rheumatology|February 17, 2015
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management RecommendationsSherry Rohekar, Jon Chan, Shirley M L Tse, et al.
The Journal of Rheumatology|February 17, 2015
2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in CanadaSherry Rohekar, Jon Chan, Shirley M L Tse, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Pageof 26

Showing results (201-210 of 260) with videos related to

Sort By:
Pageof 26
The Journal of Rheumatology|July 9, 2008
Clinical and genetic registries in psoriatic diseaseDafna D Gladman, Proton Rahman, Gerald G Krueger, et al.
The Journal of Rheumatology|December 1, 2022
Work-Related Issues and Physical and Psychological Burden in Canadian Patients With Axial Spondyloarthritis: Results From the International Map of Axial SpondyloarthritisRobert D Inman, Marco Garrido-Cumbrera, Jonathan Chan, et al.
Journal of Community Genetics|April 9, 2011
Community genetics. Its definition 2010Leo P Ten Kate, Lihadh Al-Gazali, Sonia Anand, et al.
Human Genetics|February 19, 2026
Horizon: CNV interpretation through rapid automated ACMG-aligned pathogenicity analysisMariam Eldesouky, Suhana Shiyas, Amirul Islam, et al.
Rheumatology and Therapy|August 21, 2020
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 WeeksHelena Marzo-Ortega, Philip J Mease, Proton Rahman, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
The Journal of Rheumatology|February 17, 2015
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management RecommendationsSherry Rohekar, Jon Chan, Shirley M L Tse, et al.
The Journal of Rheumatology|February 17, 2015
2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in CanadaSherry Rohekar, Jon Chan, Shirley M L Tse, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Pageof 26